Withuspharmaceutical Co.Ltd
WITHUS PHARMACEUTICAL Co.,LTD. engages in the production and sale of pharmaceutical products in South Korea. It offers circulatory agents, endocrine cost medications, osteoporosis treatment products, antithrombotic medicines, central nervous system agents, digestive tract medications, respiratory/skin preparations, musculoskeletal medications, antibiotics, antifungal and antiviral drugs, genitour… Read more
Withuspharmaceutical Co.Ltd - Asset Resilience Ratio
Withuspharmaceutical Co.Ltd (330350) has an Asset Resilience Ratio of 1.45% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2024)
This chart shows how Withuspharmaceutical Co.Ltd's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Withuspharmaceutical Co.Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩2.05 Billion | 1.45% |
| Total Liquid Assets | ₩2.05 Billion | 1.45% |
Asset Resilience Insights
- Limited Liquidity: Withuspharmaceutical Co.Ltd maintains only 1.45% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Withuspharmaceutical Co.Ltd Industry Peers by Asset Resilience Ratio
Compare Withuspharmaceutical Co.Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biostar Pharmaceuticals Inc
PINK:BSPM |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
High Sierra Technologies Inc
PINK:HSTI |
Drug Manufacturers - Specialty & Generic | 0.01% |
|
Dongwha Pharm.Co.Ltd
KO:000020 |
Drug Manufacturers - Specialty & Generic | 1.92% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.46% |
|
Yuhan Corp.
KO:000100 |
Drug Manufacturers - Specialty & Generic | 0.99% |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153 |
Drug Manufacturers - Specialty & Generic | 1.81% |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423 |
Drug Manufacturers - Specialty & Generic | 20.44% |
|
Kotra Industries Bhd
KLSE:0002 |
Drug Manufacturers - Specialty & Generic | 9.82% |
Annual Asset Resilience Ratio for Withuspharmaceutical Co.Ltd (2017–2024)
The table below shows the annual Asset Resilience Ratio data for Withuspharmaceutical Co.Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 14.03% | ₩18.89 Billion | ₩134.69 Billion | +5.47pp |
| 2023-12-31 | 8.56% | ₩11.19 Billion | ₩130.78 Billion | -13.68pp |
| 2022-12-31 | 22.24% | ₩26.56 Billion | ₩119.39 Billion | -13.46pp |
| 2021-12-31 | 35.70% | ₩42.48 Billion | ₩118.98 Billion | -1.44pp |
| 2020-12-31 | 37.14% | ₩39.43 Billion | ₩106.18 Billion | -4.61pp |
| 2019-12-31 | 41.74% | ₩44.67 Billion | ₩107.01 Billion | +4.22pp |
| 2018-12-31 | 37.52% | ₩28.62 Billion | ₩76.28 Billion | +5.67pp |
| 2017-12-31 | 31.86% | ₩21.99 Billion | ₩69.02 Billion | -- |